Correction to “Biogenic Silver Nanoparticles in Diabetes: In Vivo Mechanisms, Therapeutic Potential, and Future Perspectives: A Review”. // MedComm - Biomaterials and Applications. – 2026. – DOI: 10.1002/mba2.70091. – URL: https://onlinelibrary.wiley.com/doi/10.1002/mba2.70091?af=R
(2026). Correction to “Biogenic Silver Nanoparticles in Diabetes: In Vivo Mechanisms, Therapeutic Potential, and Future Perspectives: A Review”. MedComm - Biomaterials and Applications. https://doi.org/10.1002/mba2.70091
“Correction to “Biogenic Silver Nanoparticles in Diabetes: In Vivo Mechanisms, Therapeutic Potential, and Future Perspectives: A Review”.” MedComm - Biomaterials and Applications, 2026. doi:10.1002/mba2.70091.
@article{article84538,
title = {Correction to “Biogenic Silver Nanoparticles in Diabetes: In Vivo Mechanisms, Therapeutic Potential, and Future Perspectives: A Review”},
journal = {MedComm - Biomaterials and Applications},
year = {2026},
doi = {10.1002/mba2.70091},
url = {https://onlinelibrary.wiley.com/doi/10.1002/mba2.70091?af=R}
}
Nature Biomedical Engineering, Published online: 18 November 2026; doi:10.1038/s41551-026-01843-z Tumour-associated mucins induce the disassembly of a designer PEGylated paclitaxel-conjugated nanomedicine into small unimers that escape...